Coretherapix

ACTIVITY Coretherapix is focused on developing myocardial regeneration therapies for preventing the effects of cardiovascular disease during the acute and chronic stages of the myocardial infarction (Acute Myocardial infarction and Congestive Heart Failure, respectively).
TECHNOLOGY
  • An allogeneic cell therapy treatment (Cardiac Stem Cells)
  • A growth factor injection treatment for the acute stage and as an adjuvant to treat the chronic disease.
PRODUCTS/SERVICES
  • CTX-101: Product based on allogeneic Cardiac Stem Cells (CSC) for treating AMI and CHF expected to enter phase I in 2012.
  • CTX-201: Growth factor cocktail for treating heart attack damage.